HepC_Rwanda_McNab-02603.jpg

Featured Product:
Darunavir/ritonavir (400/50 mg) fixed-dose combination

Latest DRV/r (400/50 mg) Resources

Darunavir (DRV) is a best in class protease inhibitor commonly used in high-income markets, and has recently been prequalified by the WHO as a fixed-dose-combination with ritonavir (RTV) at a price of US $17.50/pack (EXW) for use in second-line in low- and middle-income countries. CHAI is pleased to share a set of resources to support national decision-making and implementation of this optimal product. Please contact hivtoolkit@clintonhealthaccess.org with any questions about the resources listed here.

_JJA7213.jpg

Product Adoption Resources

CHAI's DRV/r resources help countries plan for DRV/r (400/50 mg) introduction and transition.

Additional Resources Coming Soon!
 

Implementation Resources

Tools and resources to support management and coordination of product phase-in as rollout activities take place at the facility level. 

Additional Resources Coming Soon!
_JJA7098.jpg
 
img_4672_30101139356_o.jpg

Pricing, Quantification, and Monitoring Resources

Tools, guidance, and resources to support countries with budgeting, conducting quantification and supply planning, and monitoring uptake.

Additional Resources Coming Soon!